Occult hepatitis B virus infection: A case of reactivation in a patient receiving immunosuppressive treatment for allogeneic bone marrow transplantation

Blood Transfusion

Volumn 6, Issue 1, 2008, Pages 46-50

  Giudice, Cinzia Lo ^a   Martinengo, Marina ^a   Pietrasanta, Paolo ^a   Bocciardo, Laura ^a   Malavasi, Cristina ^a   Rastelli, Simona ^a   Faraci, Maura ^a   Tripodi, Gino ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LYMPHOBLAST ANTIBODY; MELPHALAN; METHOTREXATE; MITOXANTRONE; STEROID; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CONTINUOUS INFUSION; DISEASE MARKER; ERYTHROCYTE TRANSFUSION; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER FUNCTION; LOW DRUG DOSE; MALE; SEROCONVERSION; SERODIAGNOSIS; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; BONE MARROW TRANSPLANTATION; DNA, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; TRANSPLANTATION CONDITIONING;

EID: 47749119935     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0033-07     Document Type: Article

References (20)

1. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Diseases 2002; 2: 479-86.
2. Gerolami R, Henry M, Borentain P, et al. Fulminant hepatitis B associated with a specific insertion in the basal core promoter region of hepatitis B virus DNA after immunosuppressive treatment. Clin Infect Dis 2005; 40: e24-7.
3. Kitano K, Kobayashi H, Hanamura M, et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol 2006; 77: 255-8.
4. Blum HE, Offensperger WB, Walter E, et al. Latent hepatitis B virus infection with full-length viral genome in a patient serologically immune to hepatitis B infection. Liver 1988; 8: 307-16.
5. Mason AL, Xu L, Guo L, et al. Molecular basis for persistent hepatitis B infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1988; 27: 1736-42.
6. Blanpain C, Knoop C, Delforge ML, et al. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of literature. Transplantation 1998; 66: 883-6.
7. Endo T, Sawada K, Fujimoto K, et al. Reactivation of hepatitis B virus after autologous peripheral blood stem cell transplantation in patients with positive hepatitis B surface antibodies. Rinsho Ketsueki 2000; 41: 322-8.
8. Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-70.
9. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HbeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-91.
10. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred pre-emptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-9.
11. Fabrizi F, Dulai G, Dixit V, et al. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004; 77: 859-64.
12. Marzano A, Angelucci E, Andreone P, et al. for the Italian Association for the Study of the Liver (A.I.S.F.). Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
13. Hui CK, Sun J, Au WY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis virus endemic area. J Hepatol 2005; 42: 813-9.
14. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis 2005; 41: 1277-82.
15. Seth P, Alrajhi AA, Kagevi I, et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host-disease. Bone Marrow Transplant 2002; 30: 189-94.
16. Dhedin N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation. A retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998; 66: 616-9.
17. Onozawa M, Hashino S, Izumiyama K, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616-9.
18. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220.
19. Endo T, Sawada K, Fujimoto K, et al. Reactivation of hepatitis B virus after autologous peripheral blood stem cell transplantation in patients with positive hepatitis B surface antibodies. Rinsho Ketsueki 2000; 41: 322-8.
20. Brugger SA, Oesterreicher C, Hofmann H, et al. Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunised donor. Lancet 1997; 349: 996-7.